Emerg Infect Dis. 2020 Jul;26(7):1355-1363. doi: 10.3201/eid2607.181941.
Neisseria meningitidis serogroup W has emerged as an increasingly common cause of invasive meningococcal disease worldwide; the average case-fatality rate is 10%. In 2017, an unprecedented outbreak of serogroup W infection occurred among the Indigenous pediatric population of Central Australia; there were 24 cases over a 5-month period. Among these cases were atypical manifestations, including meningococcal pneumonia, septic arthritis, and conjunctivitis. The outbreak juxtaposed a well-resourced healthcare system against unique challenges related to covering vast distances, a socially disadvantaged population, and a disease process that was rapid and unpredictable. A coordinated clinical and public health response included investigation of and empiric treatment for 649 febrile children, provision of prophylactic antimicrobial drugs for 465 close contacts, and implementation of a quadrivalent meningococcal ACWY conjugate vaccine immunization program. The response contained the outbreak within 6 months; no deaths and only 1 case of major illness were recorded.
脑膜炎奈瑟菌 W 群已成为全球侵袭性脑膜炎球菌病日益常见的病因;平均病死率为 10%。2017 年,澳大利亚中部地区的土著儿童人群中发生了史无前例的 W 群感染爆发;在 5 个月期间发生了 24 例病例。这些病例中有非典型表现,包括脑膜炎球菌性肺炎、化脓性关节炎和结膜炎。该爆发使资源充足的医疗保健系统面临着覆盖大片区域、社会弱势群体以及快速且不可预测的疾病过程等独特挑战。协调的临床和公共卫生应对措施包括对 649 例发热儿童进行调查和经验性治疗,为 465 名密切接触者提供预防性抗菌药物,并实施了四价脑膜炎球菌 ACWY 结合疫苗免疫接种计划。该应对措施在 6 个月内控制了疫情;无死亡病例,仅记录到 1 例重病病例。